^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    self-amplifying RNA cancer vaccine

    i
    Other names: self-amplifying RNA cancer vaccine, RNA cancer vaccine
    Associations

    News

    Trials
    Company:
    Boehringer Ingelheim, University of California
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    almost4years
    Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC (clinicaltrials.gov)
    P1/2, N=56, Active, not recruiting, Ludwig Institute for Cancer Research | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2021 --> Oct 2021
    Clinical • Enrollment closed • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK mutation • ROS1 mutation
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • BI 1361849 • self-amplifying RNA cancer vaccine